Literature DB >> 3536205

Diabetic neuropathies and pain.

A J Boulton, J D Ward.   

Abstract

Many of the diabetic neuropathic syndromes are characterized by painful symptoms with a sensation of burning and associated with troublesome hyperaesthesia. It is important to distinguish between the acute and chronic forms of peripheral sensory neuropathy; while the former carries an excellent prognosis for symptomatic improvement within one year, the latter may cause persistent symptoms for many years. In contrast to the acute form, in which symptoms are particularly severe but abnormal neurological signs are minimal, patchy stocking and glove sensory loss together with peripheral small muscle wasting are often present in chronic sensorimotor neuropathy. Peripheral polyneuropathies are more common in patients with poor metabolic control, although recent evidence implicates blood glucose flux as a possible contributory factor to neuropathic pain. It is possible that blood glucose flux or altered peripheral blood flow leads to increased spontaneous activity in nociceptive afferent fibres which are present in the axonal sprouts that characterize small fibre neuropathy. In the diagnosis of the neuropathies, exclusion of other aetiological factors is of paramount importance as there is no specific diagnostic test for diabetic nerve damage. If there is no symptomatic improvement after a period of stable and optimal metabolic control together with simple analgesics, then the tricyclic drugs should be regarded as first line therapy. The rapid effect of these drugs suggests a peripheral rather than central mode of action.

Entities:  

Mesh:

Year:  1986        PMID: 3536205     DOI: 10.1016/s0300-595x(86)80080-9

Source DB:  PubMed          Journal:  Clin Endocrinol Metab        ISSN: 0300-595X


  12 in total

Review 1.  Aldose reductase inhibitors in the treatment of diabetic neuropathy. A review of the rationale and clinical evidence.

Authors:  E A Masson; A J Boulton
Journal:  Drugs       Date:  1990-02       Impact factor: 9.546

2.  Skeletal muscle morphology and contractile function in relation to muscle denervation in diabetic neuropathy.

Authors:  Matti D Allen; Brendan Major; Kurt Kimpinski; Timothy J Doherty; Charles L Rice
Journal:  J Appl Physiol (1985)       Date:  2013-12-19

3.  A multicentre trial of the aldose-reductase inhibitor, tolrestat, in patients with symptomatic diabetic neuropathy.

Authors:  A J Boulton; S Levin; J Comstock
Journal:  Diabetologia       Date:  1990-07       Impact factor: 10.122

4.  Current perception thresholds: a new, quick, and reproducible method for the assessment of peripheral neuropathy in diabetes mellitus.

Authors:  E A Masson; A Veves; D Fernando; A J Boulton
Journal:  Diabetologia       Date:  1989-10       Impact factor: 10.122

Review 5.  Declining Skeletal Muscle Function in Diabetic Peripheral Neuropathy.

Authors:  Prodromos Parasoglou; Smita Rao; Jill M Slade
Journal:  Clin Ther       Date:  2017-05-30       Impact factor: 3.393

6.  Does acute hyperglycaemia influence heat pain thresholds?

Authors:  A W Chan; I A MacFarlane; D R Bowsher; J C Wells
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-05       Impact factor: 10.154

7.  Intranasal insulin ameliorates experimental diabetic neuropathy.

Authors:  George Francis; Jose Martinez; Wei Liu; Thuhien Nguyen; Amit Ayer; Jared Fine; Douglas Zochodne; Leah R Hanson; William H Frey; Cory Toth
Journal:  Diabetes       Date:  2009-01-09       Impact factor: 9.461

Review 8.  Inflammatory biomarkers as a part of diagnosis in diabetic peripheral neuropathy.

Authors:  Sai Laxmi M; Prabhakar O
Journal:  J Diabetes Metab Disord       Date:  2021-01-15

9.  Referred pain in right arm from abdominal wall pseudoaneurysm.

Authors:  Soo Young Park; Seon Kyoung Ahn; Hye Young Kim; Ji Yeon Shin; Sangil Min
Journal:  Korean J Pain       Date:  2013-04-03

10.  Electroacupuncture Zusanli (ST36) on Release of Nitric Oxide in the Gracile Nucleus and Improvement of Sensory Neuropathies in Zucker Diabetic Fatty Rats.

Authors:  Pei-Jing Rong; Sheng-Xing Ma
Journal:  Evid Based Complement Alternat Med       Date:  2011-06-08       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.